Sign inJoin waitlistJoin the waitlist

Akash Nahar

Physician · Tower Health

Credentials: · · ·

History

Tower Health
Present

Research

Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087
Blood · 2019 · 274 citations
Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3…
The Lancet Oncology · 2021 · 224 citations
KEYNOTE-013 4-year follow-up of pembrolizumab in classical Hodgkin lymphoma after brentuximab vedotin failure
Blood Advances · 2020 · 42 citations

Craig Moskowitz
3 papers
Philippe Armand
3 papers
Margaret Shipp
2 papers
RR
Radhakrishnan Ramchandren
2 papers
RC
Robert Chen
2 papers
Alexander Perl
1 paper
Amer Zeidan
1 paper
Amir Fathi
1 paper
AL
Arjun Law
1 paper
Benjamin Tomlinson
1 paper
Boglarka Gyurkocza
1 paper
Brenda Sandmaier
1 paper